A Phase I/II multicenter, randomized, double-blind, dose-selecting trial to investigate the immunogenicity, reactogenicity and safety of an intradermally administered zoonotic influenza vaccine targeting H5N8 in different doses compared with intramuscular administration of the same vaccine in adults aged 40 to 80 years

Avian Influenza

HI antibody titers expressed as group GMT ratio 1 month after the second dose the H5N8 vaccine (at Day 57)., HI seroconversion rates 1 month after the second dose of the H5N8 vaccine (From Day 1 to Day 57)

Occurrence of solicited administration site AEs with onset within 7 days (i.e. from Day 1 to Day 7 included) of each study intervention administration, Occurrence of solicited systemic AEs with onset within 7 days (i.e. from Day 1 to Day 7 included) of each study intervention administration, Occurrence of unsolicited AEs with onset within 28 days (i.e. from Day 1 to Day 28 included) of each study intervention administration, Occurrence of AESIs within 6 months (i.e. from Day 1 to Day 181 included) of study intervention administration, Occurrence of SAEs within 6 months (i.e. from Day 1 to Day 181 included) of study intervention administration, Occurrence of SAEs related to study participation from signing of ICF up to end of study

No related papers found yet.